Identification of the optimal cetuximab concentration that is effective against oral squamous cell carcinoma in collagen gel droplet embedded culture drug sensitivity testing
| Autor: | Akira Tanaka, Haruka Takahashi, Kaname Sakuma, Shintaro Hanyu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Drug Cancer Research medicine.medical_specialty media_common.quotation_subject medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Internal medicine medicine neoplasms media_common Cisplatin Chemotherapy Cetuximab business.industry Cancer Articles Cell cycle medicine.disease Molecular medicine In vitro 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Molecular and Clinical Oncology. |
| ISSN: | 2049-9469 2049-9450 |
| DOI: | 10.3892/mco.2019.1953 |
| Popis: | Anticancer drug sensitivity testing using the collagen gel droplet embedded culture drug sensitivity test (CD-DST) on oral squamous cell carcinoma (OSCC) samples beginning from 2010 has been conducted. The present study investigated the effect of adding cetuximab (Erbitux(®)), a molecularly targeted drug, on anticancer drug activity against clinical OSCC specimens. A total of 25 specimens were obtained from 25 patients with OSCC between October 2013 and December 2017. The present study conducted anticancer drug sensitivity testing for cisplatin (CDDP), 5-fluorouracil (5-FU), cetuximab, three-drug combination, single agent and multi drug combinations, and cetuximab addition to the aforementioned regimens using CD-DST. In addition, the optimum concentration of each drug was evaluated. The overall evaluation success rate of the CD-DST method for OSCC specimens was 84.0% (21 of 25 cases); sensitivity to anticancer drugs and cetuximab could be evaluated. The in vitro efficacy rate of a cetuximab single agent and CDDP + 5-FU (PF) at a cut-off value of 50% was similar to the known clinical response rate. However, at a cut-off value of 50%, the in vitro efficacy of PF + cetuximab was calculated to be 40%, which was higher than the clinical response rate. The CD-DST method could be used to evaluate cetuximab, a molecularly targeted drug. Furthermore, its additive effect on conventional chemotherapy could be evaluated. The CD-DST method is suitable for evaluating and selecting chemotherapy regimens, including molecularly targeted drugs. Future studies are required to generate and evaluate relevant clinical data. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|